Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Sentinel Diagnostics

Sentinel Diagnostics develops and manufactures in-vitro diagnostic medical devices for routine analysis and specific ... read more Featured Products: More products

Download Mobile App





Sentinel Diagnostics Launches Two New Serological Tests to Quickly Assess Immunoresponse to SARS-CoV-2

By LabMedica International staff writers
Posted on 05 May 2021
Sentinel Diagnostics (Milan, Italy) has launched two new serological tests for the detection of total antibodies (IgA, IgG and IgM) to SARS-CoV-2 specific proteins in human serum that will help to quickly assess the immune response to the novel coronavirus of patients and entire communities.

The application of Sentinel’s new serological tests, COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab, would help to identify those individuals who have correctly developed antibodies after infection and/or vaccination, supporting the understanding of the degree of diffusion of COVID-19 in the community and the results of the efforts made by countries for vaccination campaigns.

Both COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab assays are In Vitro Diagnostic tests, for quantitative and qualitative analysis with immunoturbimetric method, designed to process hundreds of results in one hour and thousands in a single day when used on the company’s Sentinel SENTIFIT 270 Analyzer or other automated analytical platforms. More...
The first kit detects the total antibodies against the Spike RBD S1 protein, while the second detects the antibodies against Nucleocapsid (NC) protein.

The new Sentinel Diagnostics assays provide the first results in about 10 minutes. The use of Sentinel COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab would help distinguish vaccinated individuals from naturally infected ones. The tests can be performed together on the same serum sample or separately to better fit with laboratory needs.

"The spread of the SARS-CoV-2 pandemic and the current ongoing vaccination campaigns have raised the need for quick evaluation of the immunological status of individuals and communities to understand what measures to adopt in order to avoid spreading of infection, but also to monitor the immune response after vaccination," said Marco Buonaguidi, Head of Sales and Marketing. "We have developed our new quick solution that supports the continuous monitoring of epidemic to ensure public health decisions delivering fast results."





Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.